Subsequent Events (Details) - USD ($)		1 Months Ended	12 Months Ended
	Mar. 11, 2024	Mar. 31, 2024	Dec. 31, 2023
Subsequent events
Common stock issuance costs			$ 648,928
Subsequent Event
Subsequent events
Proceeds from sale of common stock in a private placement		$ 16,000,000
Common stock issuance costs		$ 1,400,000
Subsequent Event | Securities purchase agreement | March 2024 Private Placement | Purchasers
Subsequent events
Shares issued	1,687,712
Offering price per share	$ 7.29
Warrants to purchase of shares	507,076
Common stock with an exercise price	$ 0.001
Percentage of outstanding shares	4.99%
Proceeds from sale of common stock in a private placement	$ 16,000,000.0
Common stock issuance costs	1,400,000
Expected gross proceeds from potential future warrants cash exercise	$ 18,000,000.0
Subsequent Event | Securities purchase agreement | March 2024 Private Placement | Purchasers | At the election of holder
Subsequent events
Percentage of outstanding shares	9.99%
Subsequent Event | Securities purchase agreement | March 2024 Private Placement | Purchasers | Tranche A Warrants (Pre-funded Warrants Exercise Price 7.29 Per Share)
Subsequent events
Warrants to purchase of shares	1,097,394
Common stock with an exercise price	$ 7.29
Stock Issuance Anniversary Period	3 years
Number of days after announcement of Phase 2 dose for ATRN-119	30 days
Volume weighted average price	$ 14.58
Number of consecutive trading days	30 days
Subsequent Event | Securities purchase agreement | March 2024 Private Placement | Purchasers | Tranche B Warrants (Pre-funded Warrants Exercise Price 9.1125 Per Share)
Subsequent events
Warrants to purchase of shares	1,097,394
Common stock with an exercise price	$ 9.1125
Stock Issuance Anniversary Period	5 years
Number of days after announcement of Phase 2 dose for ATRN-119	30 days
Volume weighted average price	$ 18.225
Number of consecutive trading days	30 days